Index

Note: Page references in *italics* refer to Figures; those in **bold** refer to Tables

A to Z trial **77, 83, 172**
ABCA1 **133**
abdominal aortic aneurysm **34**
absolute risk for cardiovascular event **32**
ACCORD trial **88**
Accutane **112**
ACE inhibitors **24**
acetylcholine **21**
β-adrenergic blockers **112**
adventitia **20**
AFCAPS/TexCAPS **75**
age
  goal achievement and **12**
  LDL-C and **7**
Aggrestat-to-Zocor (A to Z) trial **77, 83, 172**
AIM-HIGH trial **88**
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) **75**
alanine aminotransferase (ALT) **81**
alcohol
  HDL and **138–9**
  triglyceride concentration and **112**
allied health professionals **59–60**
American Heart Association **130**
aneurysm, abdominal aortic **34**
angiotensin I (AI) **22**
angiotensin II (AII) **22, 23**
angiotensin converting enzyme (ACE) **23**
angiotensin converting enzyme inhibitors **24**
Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) **75, 77**
aortic aneurysm, abdominal **34**
Apo A-I **3, 133, 135–6**
Apo (a) **179**
Apo B **3, 8, 9, 13, 46**
Apo B/Apo AI ratio **46**
Apo CII deficiency **108**
Apo E2 **107**
apolipoproteins see under Apo
Apolipoprotein-Related Mortality Risk Study (AMORIS) **129**
apoptosis **23, 134**
ARBITER 2 trial **88**
arterial structure **20–1**
ASCOT-LLA **75, 77**
aspartate aminotransferase (AST) **81**
aspirin **27**
ASTEROID **83**
atherogenic dyslipidemia **74, 110, 111**
lifestyle management **111–12**
atherogenic lipid triad **73**
atherogenic lipoprotein particle number in risk assessment 12–15
atherogenic remnants 7–9
atheromatous plaques, formation 25–8
atherosclerosis 2, 34
Atherosclerosis Risk in Communities Study 6, 93, 160
atorvastatin 12, 36, 66, 67, 75, 77, 85, 172
Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) trial 92, 93, 94
autosomal dominant hypercholesterolemia 73
bezafibrate 114
Bezafibrate Infarction Prevention Study 114, 141, 142
bile acid sequestrants 5, 79–80
biomarkers 167–83, 169–70
body fat distribution, insulin resistance and 109
Bogalusa Heart Studies 162
bradykinin 21
campesterol 79
Cardiovascular Health Study 129
CARDS 77, 200, 201
CARE 77
case studies 209–24
  CAD with recent acute coronary syndrome 211–12
chest pain and gemfibrozil 219–20
dyslipidemia and rhabdomyolysis 222–3
heterozygous familial hypercholesterolemia 214
intermediate-dose statin therapy intolerance 217
ischemic stroke 218–19
low HDL-C with stable CHD and early carotid disease 220–1
metabolic syndrome 216–17
peripheral arterial disease (PAD) 212–13
severe hypertriglyceridemia 214–15
statin drug interaction with hepatotoxicity 221–2
statin-induced myalgia without myopathy 223–4
CD36 24, 73
CD40 23
CD154 23
children and adolescents 162–4, 163, 164
childhood roots of atherosclerosis 162
cholesterol screening and management in 163–4
cholesterol decline in 10
lifestyle and 2
cholesterol absorption inhibitors 77
Cholesterol and Recurrent Events (CARE) 77
cholesterol ester transfer protein (CETP) 137
Cholesterol Treatment Trialists 84
cholesteryl ester transfer protein (CETP) 110
cholestyramine 64, 79
chylomicron remnant particles 7, 9
chymase 25
Citrucel 58
claudication 34
Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial 196
clinical trials
bias and confounding 202
chance in 199–202
design issues 192–9
drug approval without 204–7
efficacy vs effectiveness 202–3
placebo and blinding 196–7
random treatment allocation 195
report evaluation 203–4
selection of study participants 192–5
validity or generalizability problems 197–9
clofibrate 114
CLPS 128
coagulation factor Va 135
colesevelam (Welchol) 205
colesevelam hydrochloride 80,
  82
colespiol 79
Collaborative AtoRvastatin Diabetes Study (CARDS) 77, 200, 201
collagen 12, 21
conjugated equine estrogens 91
Cooperative Lipoprotein Phenotyping Study (CLPS) 128
corneal arcus 74
Coronary Drug Project 142
COURAGE trial 196
C-reactive protein (CRP) 54, 168
measurement of 170–1
CXCR3 23, 25
 cyclic 5’-guanylate
monophosphate (cGMP) 21
cyclooxygenase 25, 143
cystathionine beta-synthase 181
cytochrome P450 (CYP) 3A4
pathway 75
cytokines 23, 25, 168
see also under names
DASH trial 193
diabetes 12, 34, 40, 53, 66, 88
type 1 68, 87, 157
type 2 13
diabetic dyslipidemia, management of 115–16
diaclylglycerol acyltransferase (DGAT) 114
diet 5, 52
TLC 56–8, 57, 58
Diabetic Approaches to Stop Hypertension (DASH) trial 193
direct random controlled trial 133–4
docosahexaenoic acid (DHA) 115
dysbetalipoproteinemia 13, 107
dyslipidemia 52
atherogenic 74, 110, 111–12, 111
 diabetic, management of 115–16
screening for 32–4
ECD 24
eicosapentaenoic acid (EPA) 115
elastin 21
elderly people 159–60
endothelial adhesion molecules 168
endothelial cell function and
dysfunction 21–4
endothelial nitric oxide synthase
eNOS) 21
endothelin-1 23
endothelium-derived
hyperpolarizing factor 21
ENHANCE trial 88, 90–6
epidemics 2
epidemiology of lipids 1–15
early history 2–3
estrogen 143
ethnic minorities 12, 160–2
disparities in health care 160–2, 161
risk factor incidence and prevalence in 162
European Consensus Panel on HDL-C 131
exercise 52, 53, 59
HDL and 138
ezetimibe (Zetia) 205
Expert Group on HDL Cholesterol 131
ezetimibe 77–9, 82, 88, 90–6
ezetimibe–statin combination therapy 79
familial combined hyperlipidemia 73, 87
familial defective ApoB 73
familial dysbetalipoproteinemia 13, 107
familial hypercholesterolemia 73, 87, 89, 91, 92, 93
familial hypoalphalipoproteinemia 87, 133
familial lipoprotein lipase deficiency 107
fasting lipid profile 32–3
fenofibrate 80, 88, 114, 142, 181
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial 198–9, 200, 202
fibrates 75, 80–1, 113–14, 139, 141–2
PPAR-α 115
PPAR-γ agonists 143
fibrin 21
fibrinogen 54
fibroblasts 12, 21
FIELD trial 198–9, 200, 202
fluvastatin 75, 140
foam cells 23, 25, 73, 132
Framingham Heart Study 2, 64, 117, 128, 129
Framingham Offspring Study 129
Framingham Risk Score 3, 15, 36, 131–2, 159, 209–11, 210
calculation 36–9, 37–9
for men 37
for women 38
free fatty acids, elevated, in insulin-resistant states 109
Friedewald equation 33–4
gemfibrozil 80, 114, 142
Glogovian remodeling 26, 26
glucose intolerance 52
glutathione peroxidase 134
glycoprotein IIb/IIIa inhibitors 27
guanylate cyclase 21
HATS trial 88
HDL 3, 33
antiatherogenic 132–7, 136
guideline definitions 131, 132
insulin resistance and 137
lifestyle modification on serum 137–9
relationship between, and risk for CVD 128–30
treatment goals 131–2, 143–5
HDL-cholesterol (HDL-C) 3
and CHD risk 9–10
depressed, management 127–46
low, prevalence of 130–1
pharmacologic management 139–43, 140, 141
as targets for therapy 41
Heart and Estrogen/Progestin Replacement Study (HERS) 198
Heart Protection Study (HPS) 67–8, 77, 140
heat shock proteins (HPS) 23
Helsinki Heart Study 141
hemorrhagic stroke 84–5
heparin sulfate 21
hepatic ligase (HL) 73, 137
hepatic lipase deficiency 107–8
hepatic steatosis, non-alcohol 88
hepatotoxicity 81
HERS 198
Hiaspan 143
high-density lipoproteins see under HDL
high-risk patient identification 67
treatment 68
high-sensitivity C-reactive protein (hsCRP)
as risk factor/biomarker 171–2, 171
as target of therapy for CHD 172–3
use for stratifying CHD risk 173
HM74A 142
homocysteine 168, 181–2
hormone sensitive lipase 142
HPS 67–8, 77, 140
hydrogen peroxide 23
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase 74
7α-hydroxylase 79, 134
hydroxymethylglutaryl coenzyme A inhibitors see statins
hyperalphalipoproteinemia 133
hypercholesterolemia 53
autosomal dominant 73
familial 73, 87, 89, 91, 92, 93
primary (type II hyperlipoproteinemia) 80
hyperhomocysteinemia 181, 182
hyperlipidemia, familial combined 73, 87
hypertension 5, 52, 53
hypertriglyceridemia 7, 87–8, 140, 142
atherogenic dyslipidemia and 110, 111
insulin resistance and 108
hyaloalphalipoproteinemia 87, 133
hypothyroidism 160
IDEAL 83
ileal bypass surgery 5
Improved Reduction of Outcomes: VYTORIN Efficacy International trial 95
IMPROVE-IT 88, 95
Incremental Decrease Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER) 77
indirect random controlled trial (RCT) 133
inducible protein-10 (IP-10) 23, 25
inflammation 52, 168
insulin resistance 54, 73, 87
body fat distribution 109
HDL and 137
hypertriglyceridemia and 108
in nonobese patient 109–10
intercellular adhesion molecule-1 (ICAM-1) 21, 168
intercellular matrix molecules 12
interferon-inducible T-cell alpha-chemoattractant (I-TAC) 23, 25
interferon-γ 23, 25
INTERHEART study 3
interleukins
IL-1 23, 25, 168
IL-4 23
IL-6 170
IL-10 23
intermediate-density lipoprotein (IDL) 7, 9
intima 20, 21
Intralipid 109

LDL 3, 8, 33, 133
oxidized 134
LDL particle number 168, 182–3
LDL cholesterol (LDL-C) 9
associated genetic disorders 73
atherogenic impact 73–4
benefits of reduction 90–6
CHD as function of 128, 129
CHD risk and 4–5, 5
elevated 63–98
lowering to achieve
Non-HDL-C goal 112–13
lowering, and CHD risk reduction 6–7, 6
management 74–82
mutations 6
as predictor of CHD 13
reduction, high risk and, clinical trial support for 66–8
and risk for cardiovascular events 64–5
risk of very low serum level 82–5
treatment goals 3
vs atherogenic particles as primary target for therapy 42–7, 44
lecithin cholesteryl acyltransferase (LCAT) 133
lectin-like oxidized low-density lipoproteins receptor-1 (LOX-1) 24–5
lifestyle changes 51–60
lifetime risk for CVD 4
LIPID 77
lipid-lowering medications, potential toxicities 81–2
lipid management, trends in the USA 10
Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) 10, 64, 80, 197–8
Lipid Research Clinics Prevalence Mortality Follow-up Study 129
lipid risk factors 3–4
Lipid Treatment Assessment Program 10, 12
lipids, trends in the USA 10
lipoprotein lipase deficiency, familial 107
5’-lipoxygenase 25, 134
Lipoprotein and Coronary Atherosclerosis Study 140
lipoprotein lipase 107, 137, 141
lipoprotein(a) 9, 168, 179–81, 180
lipoprotein-associated phospholipase A2 25, 134, 174–9, 176–7, 177
liver function tests (LFTs) 81
Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) 77
lovastatin 75
Lovaza 115
low-density lipoproteins see under LDL
LRC-CPPT 10, 64, 80, 197–8
lymphocytes 21, 24–5
lysophosphatidylcholine 175
macrophage colony stimulating factor (M-CSF) 24
macrophages 23, 132
mast cells 25
matrix metalloproteinases (MMPs) 23, 25
media 20–1
medroxyprogesterone acetate 91, 144
MESA 120–1
metabolic syndrome (MetS) 9, 40, 54–5, 66, 87, 108
criteria for clinical diagnoses 55
incidence 130
lifestyle management for 111–12
low HDL-C in 130–1
Metamucil 58
methylene tetrahydrofolate reductase 181
monocyte chemoattractant protein-1 (MCP-1) 21
monocytes 21–2, 23
role of 24–5
mortality from CHD 1
MRFIT 64, 85, 129, 198
Multi-Ethnic Study of Atherosclerosis (MESA) 120–1
Multiple Risk Factor Intervention Trial (MRFIT) 64, 85, 129, 198
muraglitazar 204
myalgia 81–2, 87
myeloperoxidase 25, 134, 168, 174, 175
myocardial infarction 27
nascent discoidal high-density lipoprotein (ndHDL) 133
National Cholesterol Education Program (NCEP) 130
National Cholesterol Education Program ATP (Adult Treatment Panel) III 3, 10, 11, 12, 13, 32, 34, 54, 57, 83, 144, 205, 209
classification of lipoprotein 33, 39–41, 106
National Cholesterol Education Program Evaluation Project using Novel E-Technology (NEPTUNE) II survey 10–12, 11, 41, 45, 54, 106, 157, 158, 161
National Health and Nutrition Examination Surveys 10
National Lipid Association Statin Safety Assessment Task Force 81
NEPTUNE II survey 10–12, 11, 41, 45, 54, 106, 157, 158, 161
niacin 80–1, 88, 114–15, 139, 142–3
Niaspan 114
nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) oxidase 23
Nieman Pick C1 like-1 protein 77, 78, 91
nitric oxide (NO) 21, 22
non-CHD atherosclerosis 12
non-HDL-C (high-density lipoprotein cholesterol) 3, 8–9, 8, 34
elevated, management of 105–23
clinical factors 106–7
as predictor of CHD 13
non-ST-segment elevating myocardial infarction (NSTEMI) 27
Northern Manhattan Stroke Study 129
obesity 52, 53, 108
patterns of 109
oestrogens, oral 112
omega-3 fatty acids 115
omega-3 fish oils 88
oxidized LDLs 168
PAI-1 24
pancreatitis 40, 107
paracytosis 22
paraoxomas 134
Pathobiological Determinants of Atherosclerosis in Youth Study 162
peripheral arterial disease 4
peroxide 23
peroxisomal proliferator-activated receptor-α (PPAR-alpha) see fibrates
phospholipase A2 168
physical activity see exercise
Physicians’ Health Study 128
Pim Indians, lifestyle and CHD risk factors 52–3
pioglitazone 116
plant sterols/stanols 58, 113
plasminogen activator inhibitor (PAI) 21
platelet activating factor acetylhydrolase (PAF-AH) see lipoprotein-associated phospholipase A2
platelet-derived growth factor 22
platelet factor 4 22
positive remodeling 26, 26
pravastatin 67, 75, 140
Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE-IT-TIMI) 22, 66–7, 83, 172, 173
Prospective Cardiovascular Munster Study 128
Prospective Epidemiological Study of Myocardial Infarction 128–9
PROSPER 77
prostacyclin (prostaglandin I2) 21
prostaglandin D2 143
protein C 13
protein S 135
PROVE-IT TIMI 22, 66–7, 83, 172, 173
reactive oxygen species 23, 23, 25
retinoids 112
revascularization procedures 4
REVERSAL 83, 172
Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) 83, 172
reverse cholesterol transport (RCT) 132–3, 135
rhabdomyolysis 81, 88, 142
rheumatoid arthritis 170
risk categories 35–6
risk factors 2–3, 4, 20, 24, 34, 52, 167–83
lifestyle factors as determinants 53
nature and nurture 52–3
therapeutic lifestyle changes 55–6, 56
treatment goals 35
within country variations in lifestyle and 53–4
risk stratification 34–6
rofecoxib (Vioxx) 204
rosiglitazone (Avandia) 116, 205
rosuvastatin 36, 75
SANDS 95
Scandinavian Simvastatin Survival Study 64–5, 65, 66
scavenger receptor A 24, 73
scavenger receptor B-I (SR-BI) 133
scavenger receptor for phosphatidyl serine and oxidized low-density lipoproteins (SR-PSOX) 25
SEARCH 182
selectin L 168
selectin P 168
selectins 21
Seven Countries Study 2, 53
simvastatin (Zocor) 12, 36, 38, 67, 75, 172
in women 157, 158
simvastatin/ezetimibe combination therapy 88
sitosterol 79
β-sitosterolemia 79
smoking 12, 40, 52, 66
cessation 9, 59
HDL and 138, 139
insulin sensitivity 111
smooth muscle cells (SMC) 12, 25
SPARCL study 85
statins 5, 10, 24, 66, 74–7, 139, 140
effects on LDL-C, non-HDL-C and Apo B 13, 14
efficacy in reducing CHD risk 69–72
high-dose, vs combination lipid rug therapy 87–9
in lowering LDL-C 112–13
pleiotropic effects 75, 76
Stop Atherosclerosis in Native Diabetics Study (SANDS) 95
stroke 4, 34
ST-segment elevating myocardial infarction (STEMI) 27
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) trial 182
substance P 21
superoxide 23, 23
T cells 23, 25
T helper cells (TH1 25, TH2 25)
T lymphocytes 23, 25
TG-rich lipoprotein clearances, disorders of 107–8
thalidomide 192
thiazide diuretics 112
thiazolidinediones (TZDs) 116, 143
thiolase 181
thrombomodulin 21
thrombospondin 22
thromboxane A2 135
tissue factor (TF) 23, 25
tissue plasminogen activator (tPA) 21
therapeutic lifestyle changes (TLC) 56–7, 57, 58, 131
TNT 66, 77, 83
torcetrapib 91, 204, 206
total circulating cholesterol level 33
total/HDL cholesterol ratio, targets for 41–2, 42, 43
trans fats 57
transcytosis 22
transforming growth factor-β 22
transient ischemic attack 34
treating to new targets (TNT) trial 66, 77, 83
triglycerides 7
clinical factors 106–7
elevated, management of 105–23
elevated, treatment goals 40–1
as targets for therapy 41
treatment and LDL particle size 116–22
Tromso Heart Study 128
tryptase 25
tumor necrosis factor (TNF) 23, 25
TNF-α 168
unstable angina 27
uric acid 54
urokinase 135
US Nurses’ Health Study 53
US Physician’s Health Study 54
VA-HIT 120, 142
vasa vasora 21, 27
vascular cell adhesion molecule 1 (VCAM-1) 21, 168
vascular remodeling 26
very low-density lipoprotein (VLDL) 3, 7, 8, 33, 133
Veterans Administration High-Density Lipoprotein Intervention Trial (VA-HIT) 120, 142
viscous fibers 113
very low-density lipoprotein (VLDL) 108
very low-density lipoprotein-cholesterol VLDL-C 7, 9, 33, 57
weight and weight loss 59, 137–8
West of Scotland Coronary Prevention Study (WOSCOPS) 77
women 12
cardiovascular disease risk in 156
dyslipidemia treatment in 157–9
lipids in 157
sex hormone therapy, lipids and CVD risk in menopause 159
WOSCOPS 77
xanthine oxidase 23
xanthomas, plantar and periosteal 74
Zetia 205